Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Acasunlimab |
| Synonyms | |
| Therapy Description |
Acasunlimab (GEN1046) is a bispecific antibody that binds to and simultaneously targets PD-L1 and TNFRSF9 (4-1BB), potentially resulting in T-cell activation leading to increased anti-tumor immune response and decreased tumor growth (PMID: 35176764). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Acasunlimab | GEN1046|GEN-1046|GEN 1046|DuoBody-PD-L1x4-1BB|BNT 311|BNT-311|BNT311 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 TNFRSF9 Antibody 36 | Acasunlimab (GEN1046) is a bispecific antibody that binds to and simultaneously targets PD-L1 and TNFRSF9 (4-1BB), potentially resulting in T-cell activation leading to increased anti-tumor immune response and decreased tumor growth (PMID: 35176764). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05117242 | Phase II | Acasunlimab + Pembrolizumab Acasunlimab | Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | 1 |
| NCT03917381 | Phase Ib/II | Acasunlimab | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | Active, not recruiting | USA | TUR | POL | ITA | ISR | HUN | ESP | CZE | 2 |
| NCT06984328 | Phase II | Acasunlimab Acasunlimab + Pembrolizumab | Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07) | Active, not recruiting | USA | 1 |